Pluristem Therapeutics Inc. (PSTI) Income Statement Analysis

See more : Defense Metals Corp. (DFMTF) Income Statement Analysis – Financial Results

Complete financial analysis of Pluristem Therapeutics Inc. (PSTI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pluristem Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Pluristem Therapeutics Inc. (PSTI)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.pluristem.com

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Metric	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	0.00	23.00K	54.00K	50.00K	0.00	2.85M	379.00K	379.00K	679.00K	716.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	2.00K	2.00K	0.00	100.00K	13.00K	11.00K	20.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	23.00K	52.00K	48.00K	0.00	2.75M	366.00K	368.00K	659.00K	716.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	100.00%	96.30%	96.00%	0.00%	96.49%	96.57%	97.10%	97.05%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	30.07M	21.58M	26.43M	22.63M	21.09M	19.58M	19.17M	19.54M	17.23M	9.18M	6.63M	4.30M	3.14M	4.39M	2.55M	1.30M	1.79M	1.22M	79.87K	0.00
General & Administrative	20.56M	7.92M	9.16M	11.19M	6.93M	6.49M	6.46M	8.68M	5.65M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	20.56M	7.92M	9.16M	11.19M	6.93M	6.49M	6.46M	8.68M	5.65M	6.57M	4.49M	3.14M	3.42M	6.04M	3.73M	1.03M	873.65K	1.78M	130.62K	74.45K
Other Expenses	0.00	0.00	0.00	-43.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	168.62K	0.00	0.00	0.00
Operating Expenses	50.62M	29.50M	35.58M	33.78M	28.02M	26.07M	25.63M	28.22M	22.88M	15.75M	11.11M	7.44M	6.56M	10.43M	6.28M	2.33M	2.83M	3.00M	210.49K	74.45K
Cost & Expenses	50.62M	29.50M	35.59M	33.78M	28.02M	26.17M	25.65M	28.23M	22.90M	15.75M	11.11M	7.44M	6.56M	10.43M	6.28M	2.33M	2.83M	3.00M	210.49K	74.45K
Interest Income	492.00K	384.00K	385.00K	276.00K	122.00K	149.00K	112.00K	246.00K	266.00K	575.00K	236.00K	2.00K	14.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	78.00K	196.00K	0.00	0.00	0.00	0.00	0.00	0.00	29.00K	12.00K	13.00K	31.00K	8.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.37M	1.57M	1.96M	2.02M	2.18M	2.15M	2.07M	1.90M	1.03M	435.00K	312.00K	207.00K	173.00K	129.00K	224.72K	264.83K	202.85K	153.64K	21.04K	-3.45K
EBITDA	-48.42M	-27.39M	-33.35M	-24.11M	-25.64M	-21.10M	-22.60M	-25.03M	-20.09M	-14.35M	-10.52M	-7.22M	-6.46M	-10.37M	-8.20M	-2.17M	-1.90M	-1.86M	-441.96K	-77.90K
EBITDA Ratio	0.00%	-119,069.57%	-61,750.00%	-48,216.00%	0.00%	-740.99%	-5,963.85%	-6,604.22%	-2,959.20%	-2,003.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-50.62M	-29.48M	-35.53M	-33.73M	-28.02M	-23.32M	-25.27M	-27.85M	-22.22M	-15.03M	-11.11M	-7.44M	-6.56M	-10.43M	-6.28M	-2.33M	-2.83M	-3.00M	-456.96K	-74.45K
Operating Income Ratio	0.00%	-128,156.52%	-65,800.00%	-67,462.00%	0.00%	-819.07%	-6,666.75%	-7,348.28%	-3,272.90%	-2,099.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	758.00K	324.00K	225.00K	7.61M	205.00K	73.00K	590.00K	918.00K	1.07M	237.00K	43.00K	-17.00K	-84.00K	0.00	-1.96M	0.00	740.96K	0.00	-246.47K	0.00
Income Before Tax	-49.87M	-29.15M	-35.31M	-26.13M	-27.81M	-23.25M	-24.68M	-26.93M	-21.16M	-14.79M	-11.07M	-7.46M	-6.64M	0.00	-8.24M	0.00	-2.09M	0.00	-703.43K	0.00
Income Before Tax Ratio	0.00%	-126,747.83%	-65,383.33%	-52,252.00%	0.00%	-816.51%	-6,511.08%	-7,106.07%	-3,115.61%	-2,066.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	836.00K	520.00K	225.00K	7.61M	205.00K	73.00K	590.00K	918.00K	1.10M	249.00K	56.00K	14.00K	-76.00K	0.00	-1.96M	0.00	740.96K	0.00	-246.47K	3.45K
Net Income	-49.87M	-29.15M	-35.31M	-26.13M	-27.81M	-23.25M	-24.68M	-26.93M	-21.16M	-14.79M	-10.85M	-7.45M	-6.64M	-10.50M	-8.43M	-2.44M	-2.10M	-2.01M	-463.00K	-77.90K
Net Income Ratio	0.00%	-126,747.83%	-65,383.33%	-52,252.00%	0.00%	-816.51%	-6,511.08%	-7,106.07%	-3,115.61%	-2,066.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-1.77	-1.60	-2.86	-2.47	-3.18	-2.92	-3.51	-4.24	-3.81	-3.36	-3.48	-4.38	-6.26	-16.35	-58.44	-80.00	-126.90	-165.99	-24.79	-4.45
EPS Diluted	-1.77	-1.60	-2.86	-2.47	-3.18	-2.92	-3.51	-4.24	-3.81	-3.36	-3.48	-4.38	-6.26	-16.35	-58.44	-80.00	-126.90	-160.00	-24.79	-4.45
Weighted Avg Shares Out	28.11M	18.20M	12.33M	10.59M	8.74M	7.95M	7.03M	6.35M	5.55M	4.40M	3.12M	1.70M	1.06M	642.24K	144.24K	30.50K	16.53K	12.11K	18.68K	17.50K
Weighted Avg Shares Out (Dil)	28.11M	18.20M	12.33M	10.59M	8.74M	7.95M	7.03M	6.35M	5.55M	4.40M	3.12M	1.70M	1.06M	642.24K	144.24K	30.50K	16.53K	12.57K	18.68K	17.50K

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

July 14, 2022zacks.com

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

July 13, 2022benzinga.com

Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture. The 240-subject study did not meet the primary endpoint, the Short.

Best Penny Stocks to Buy as January Ends? 4 to Watch

January 22, 2022pennystocks.com

Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your List in January

January 10, 2022pennystocks.com

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

January 10, 2022benzinga.com

Pluristem Therapeutics Inc (NASDAQ: PSTI) and Tnuva Group have collaborated to develop, manufacture and commercialize cultured cell-based products for the food industry. Tnuva Group is the largest food producer in Israel and the Israeli player in the field of alternative dairy and protein...

Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS

December 28, 2021zacks.com

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Pluristem CEO Issues Shareholder Update

September 22, 2021globenewswire.com

HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.

Pluristem Appoints Prof. Varda Shalev MD and Mr.

July 19, 2021globenewswire.com

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the...

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

July 8, 2021globenewswire.com

HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 Phase II studies to clinical readout....